BACKGROUND: CD4+ lymphocytes control Mycobacterium tuberculosis infection through cytokine-mediated macrophage activation. Extrapulmonary tuberculosis is presumably a marker of immunodeficiency, but cytokine responses have not been well studied in such patients. OBJECTIVE: Assess immune defects in persons with previous extrapulmonary tuberculosis. METHODS: In vitro cytokine responses of PBMCs from HIV-seronegative adults with previous extrapulmonary tuberculosis (n = 10) were compared with responses from persons with previous pulmonary tuberculosis (n = 24) and latent M tuberculosis infection (n = 30) in a case-control study. RESULTS: Patients and controls did not differ according to age, sex, race, or monocytes. The median time between tuberculosis diagnosis and study entry was 72 and 122 weeks in extrapulmonary and pulmonary patients, respectively (P = .2). Median CD4+ counts were 660, 814, and 974 lymphocytes/mm3 in extrapulmonary, pulmonary, and latently infected patients, respectively (P = .03). At 48 hours, median unstimulated cytokine levels were uniformly lower in extrapulmonary patients than both sets of controls. These differences persisted after controlling for CD4+ count by linear regression analysis. Despite lower unstimulated levels, median TNF-alpha response was higher in patients with extrapulmonary and pulmonary tuberculosis than latently infected persons after stimulation with PHA 1% (P = .006) and PHA+IL-12 (1 ng/mL; P = .02); IL-10 remained low in patients with extrapulmonary tuberculosis after the same stimuli (P = .04 and .06, respectively). There was no primary immunodeficiency in the IL-12/23-IFN-gamma axis. CONCLUSION: HIV-seronegative adults with previous extrapulmonary tuberculosis had lower CD4+ lymphocytes and unstimulated cytokine production. This suggests a subtle abnormality in innate immune function. CLINICAL IMPLICATIONS: These characteristics could identify persons at risk for severe tuberculosis manifestations.
BACKGROUND:CD4+ lymphocytes control Mycobacterium tuberculosis infection through cytokine-mediated macrophage activation. Extrapulmonary tuberculosis is presumably a marker of immunodeficiency, but cytokine responses have not been well studied in such patients. OBJECTIVE: Assess immune defects in persons with previous extrapulmonary tuberculosis. METHODS: In vitro cytokine responses of PBMCs from HIV-seronegative adults with previous extrapulmonary tuberculosis (n = 10) were compared with responses from persons with previous pulmonary tuberculosis (n = 24) and latent M tuberculosis infection (n = 30) in a case-control study. RESULTS:Patients and controls did not differ according to age, sex, race, or monocytes. The median time between tuberculosis diagnosis and study entry was 72 and 122 weeks in extrapulmonary and pulmonary patients, respectively (P = .2). Median CD4+ counts were 660, 814, and 974 lymphocytes/mm3 in extrapulmonary, pulmonary, and latently infectedpatients, respectively (P = .03). At 48 hours, median unstimulated cytokine levels were uniformly lower in extrapulmonary patients than both sets of controls. These differences persisted after controlling for CD4+ count by linear regression analysis. Despite lower unstimulated levels, median TNF-alpha response was higher in patients with extrapulmonary and pulmonary tuberculosis than latently infectedpersons after stimulation with PHA 1% (P = .006) and PHA+IL-12 (1 ng/mL; P = .02); IL-10 remained low in patients with extrapulmonary tuberculosis after the same stimuli (P = .04 and .06, respectively). There was no primary immunodeficiency in the IL-12/23-IFN-gamma axis. CONCLUSION: HIV-seronegative adults with previous extrapulmonary tuberculosis had lower CD4+ lymphocytes and unstimulated cytokine production. This suggests a subtle abnormality in innate immune function. CLINICAL IMPLICATIONS: These characteristics could identify persons at risk for severe tuberculosis manifestations.
Authors: Pradyumna Kumar Mishra; A Bhargava; R P Punde; N Pathak; P Desikan; A Jain; S Varshney; K K Maudar Journal: Indian J Clin Biochem Date: 2010-05-27
Authors: M A Huaman; C T Fiske; T F Jones; J Warkentin; B E Shepherd; L A Ingram; F Maruri; T R Sterling Journal: Epidemiol Infect Date: 2014-08-22 Impact factor: 2.451
Authors: Christina T Fiske; Alexandre S de Almeida; Ayumi K Shintani; Spyros A Kalams; Timothy R Sterling Journal: Clin Vaccine Immunol Date: 2012-06-06
Authors: Alison A Motsinger-Reif; Paulo R Z Antas; Noffisat O Oki; Shawn Levy; Steven M Holland; Timothy R Sterling Journal: BMC Med Genet Date: 2010-03-02 Impact factor: 2.103
Authors: Noffisat O Oki; Alison A Motsinger-Reif; Paulo Rz Antas; Shawn Levy; Steven M Holland; Timothy R Sterling Journal: BMC Res Notes Date: 2011-01-31
Authors: Christina T Fiske; Marie R Griffin; Holt Erin; Jon Warkentin; Kaltenbach Lisa; Patrick G Arbogast; Timothy R Sterling Journal: BMC Infect Dis Date: 2010-01-22 Impact factor: 3.090